Life sciences are at a critical inflection point, where scientific innovation, regulatory demands, and patient expectations converge with advances in data and artificial intelligence, positioning IT as a central driver of faster and more effective drug discovery and clinical development. This week, Dave and Rob continue with part 2 off the Life Sciences mini-series with Dr. Alex Zhavoronkov founder and CEO of Insilico Medicine to exploring how drug discovery and clinical development can become faster and more effective, and the role of AI in that process. TLDR 00:40 – Introduction 01:00 – Hang out: Kill Bill Vol. 1 &amp; 2 03:07 – Dig in: Life Sciences mini-series, Part 2 06:43 – Conversation with Dr Alex Zhavoronkov 42:12 – The future of AI in drug discovery and a new paradigm for pharma Guest Dr. Alex Zhavoronkov: https://www.linkedin.com/in/zhavoronkov/ Hosts Dave Chapman: https://www.linkedin.com/in/chapmandr/ Esmee van de Giessen: https://www.linkedin.com/in/esmeevandegiessen/ Rob Kernahan: https://www.linkedin.com/in/rob-kernahan/ Production Marcel van der Burg: https://www.linkedin.com/in/marcel-vd-burg/ Dave Chapman: https://www.linkedin.com/in/chapmandr/ Sound Ben Corbett: https://www.linkedin.com/in/ben-corbett-3b6a11135/ Louis Corbett: https://www.linkedin.com/in/louis-corbett-087250264/ &#x27;Realities Remixed&#x27; is an original podcast from Capgemini

RRSP02 The state of Life Sciences, pt 2 - How AI relates to human life and longevity with Dr. Alex Zhavoronkov Insilico Medicine

Realities Remixed

# Full Transcript

**Podcast:** Realities Remixed

## Transcript

Well, just to add to that, so you know, we actually at Insilico, we designed our own clothing where we show performance metrics. No way! People like to wear it. We also operate in Asia quite actively and there people actually like to demonstrate their achievements on their clothing. I will not be electing one of those for me to demonstrate my achievements. To be very clear.

I'm Dave Chapman. I'm Rob Kernahan. And this is Realities Remixed, an original podcast from Capgemini. And this week it is part two of the Life Sciences mini-series and we're going to have a look at drug discovery, clinical development and how it can become faster and more effective with the use of AI in the process and maybe some big thinking. Joining us as usual for the Life Sciences mini-series, I'm delighted to say it's our friend Torsten Rahl, who's Life Sciences leader here at Capgemini.

Torsten, how are you doing today? Doing perfectly fine. Great to be with you again. Great to see you mate. And Roberto, you're here? Hello. How are you? I'm here. It's Friday. How are you doing? Uh, hashtag winning. Don't know. Living the dream. All of those above. Happy Friday from Robert. Happy Friday everyone. I'm hoping for a big conversation on this one. So, uh, looking forward to it.

Let's go. Marcel's also here now. And I'm going to bring Marcel in unusually because Marcel went to see the whole bloody affair this week, Marcel. Yeah. Bill, Bill, the whole thing. Bill, Bill, one and two. One take, four and a half hours. Now, what did you make of it? Did you fall asleep? No, no. Had, had, uh, many laughs with a friend. Um, good popcorn of course. It's not a comedy film, Marcel. You have spotted that, right? It's got quite a series. I was like, laughs and kill Bill, I'd say.

There, there are scenes in it where you, you must laugh at it. So, uh, yeah, just, just enjoyed it for four and a half hours. Straightforward as, as Tarantino meant it to be. Now, here's the big question. Did you prefer it as one big tacked together film or did you prefer it as part one, part two? No, one, one combined together. Did you? Much better. Did you? Yeah. Yeah. Torsten, have you seen, have you seen this big kill Bill?

I've, I've only seen one and two separately. I haven't seen it as one big film and it's been a while, but I must say it's like an interesting introduction into like a life science podcast. It's kind of, I don't know. Kill Bill is more like death science to, to, to. That is true. The other is a special introduction for sure. Certainly something about life. Yeah. I think somewhere, um, I'm, I'm on record as part one and part two better. I think just to, they're a bit different, aren't they?

A little bit different. Anyway, let's get onto our main subject of life sciences. Torsten, remind us of what we're covering in the mini series. Sure. We're happy to. So, um, we essentially going to look at the full value chain of, uh, ...

RRSP02 The state of Life Sciences, pt 2 - How AI relates to human life and longevity with Dr. Alex Zhavoronkov Insilico Medicine

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

RRSP02 The state of Life Sciences, pt 2 - How AI relates to human life and longevity with Dr. Alex Zhavoronkov Insilico Medicine

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.